ASX:TLX

Telix Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume746,789 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive TLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Telix Pharmaceuticals (ASX:TLX) Frequently Asked Questions

What stocks does MarketBeat like better than Telix Pharmaceuticals?

Wall Street analysts have given Telix Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Telix Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Telix Pharmaceuticals' next earnings date?

Telix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 18th 2021.
View our earnings forecast for Telix Pharmaceuticals
.

Who are Telix Pharmaceuticals' key executives?

Telix Pharmaceuticals' management team includes the following people:
  • Dr. Christian P. Behrenbruch Ph.D., BEng(Hons), MBA, DPhil(Oxon), J.D., GAICD, Co-Founder, MD, CEO & Exec. Director (Age 45, Pay $375.02k)
  • Mr. Douglas Cubbin FCPA, GAICD, Group Chief Financial Officer
  • Dr. Gabriel Liberatore B.Sc., M.A.I.C.D., M.B.A., Ph.D., Group Chief Operating Officer
  • Mr. Harry Marfatia, Director of Corp. Fin.
  • Dr. Michael Wheatcroft Ph.D., Ph.D., (Cantab), BSc(Hons), Chief Scientist
  • Mr. Jonathan Barlow B.Sc., L.L.B., Chief Bus. Devel. Officer & Group Gen. Counsel
  • Ms. Amanda Griffin, Communications Mang.
  • Mr. Christian Davis, VP Sales and Marketing, EMEA
  • Ms. Margaret Haarhoff B.A., Global Director of People & Culture
  • Dr. Jyoti Arora BappSc(Hons), Ph.D., Chief Operating Officer (APAC)

Who are some of Telix Pharmaceuticals' key competitors?

What other stocks do shareholders of Telix Pharmaceuticals own?

What is Telix Pharmaceuticals' stock symbol?

Telix Pharmaceuticals trades on the ASX under the ticker symbol "TLX."

How much money does Telix Pharmaceuticals make?

Telix Pharmaceuticals has a market capitalization of $0.00 and generates $5.21 million in revenue each year.

What is Telix Pharmaceuticals' official website?

The official website for Telix Pharmaceuticals is www.telixpharma.com.

How can I contact Telix Pharmaceuticals?

The company can be reached via phone at 61 4 4914 8448.


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.